Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.23.3
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 8,256 6,578 27,649 21,312
General and administrative 3,425 3,448 12,580 10,887
Operating expenses 11,681 10,026 40,229 32,199
Other income/(expense):        
Interest income 232 254 980 387
Foreign exchange gain/(loss) 2 (5) (3) (11)
Total other income 234 249 977 376
Net loss (11,447) (9,777) (39,252) (31,823)
Other comprehensive loss:        
Unrealized gain (loss) on available-for-sale securities 0 20 3 (17)
Total comprehensive loss $ (11,447) $ (9,757) $ (39,249) $ (31,840)
Basic loss per common share (in dollars per share) $ (1.76) $ (1.59) $ (6.14) $ (5.17)
Diluted loss per common share (in dollars per share) $ (1.76) $ (1.59) $ (6.14) $ (5.17)
Weighted average number of common shares outstanding (in thousands) used in the calculation of basic loss per common share (in shares) 6,495 6,153 6,391 6,150
Weighted average number of common shares outstanding used in the calculation of diluted loss per common share ( in shares) 6,495 6,153 6,391 6,150